In addition, Knight may pay future contingent payments of up to US$15 million upon achieving certain sales milestones. In 2024, Paladin generated revenues of $70 million excluding products that ...
Knight Therapeutics Inc. GUD-T has signed a deal to buy the assets of Paladin Pharma Inc. as the Canadian drug company looks to build out its domestic business after a strategic push into South ...
Davies Ward Phillips & Vineberg LLP; Paladin Pharma Inc. Knight Therapeutics Inc. has entered into a definitive Asset Purchase Agreement (“APA”) with Endo Operations Limited (“Endo”) and Paladin ...
In addition, Knight may pay future contingent payments of up to US$15 million upon achieving certain sales milestones. In 2024, Paladin generated revenues of $70 million excluding products that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback